World's First Invasive Brain-Computer Interface Receives Market Approval in China
neuracle
Developer of Rehabilitation Assistance Systems
Andon Health
Developer and Manufacturer of Health-related Electronic Products and Smart Hardware
Biolight
Medical Device R&D Manufacturer
| Lead Rise Individual Thigh |
Name | Relevant | Price Change |
|---|---|---|---|
| *ST SiHuan | Research Report Cash Flow | 4.12% | |
| Sino Cells | Research Report Cash Flow | 3.53% | |
| Opmay | Research Report Cash Flow | 2.82% | |
| Baili Tianheng | Research Report Cash Flow | 2.39% | |
| Click to view all>> | |||
| Resources Gold Flow Enter |
Name | Relevant | Net Inflow (10,000) |
|---|---|---|---|
| Changchun High & New | Research Report Cash Flow | 3095.08 | |
| Rongchang Bio | Research Report Cash Flow | 2389.15 | |
| Junshi Biosciences-U | Research Report Capital Flow | 1636.82 | |
| Tonghua Dongbao | Research Report Cash Flow | 1538.74 | |
| Click to view all>> | |||
Industry Perspective:
Weekly Review. Last week (March 9 - March 13), the pharmaceuticals and biotechnology sector fell by 0.22%, underperforming the CSI 300 Index (0.19%). Among the sub-sectors, medical consumables (4.1%), active pharmaceutical ingredients (1.32%), and vaccines (1.29%) were the top gainers, while medical devices (-2.04%), medical R&D outsourcing (-1.63%), and chemical preparations (-0.82%) were the worst performers. In terms of individual stocks, Andon Health (20.1%), Guangdong Biolight Meditech (17.8%), and Wuhan Hiteck Biological Pharma (17%) saw the largest increases, whereas Neuracle (-6.9%), ST Unnamed (-6.8%), and Yirui Technology (-6.7%) experienced the biggest declines.
The First Approval for Invasive Brain-Computer Interface Granted. On March 5, the government work report listed brain-computer interface as a future industry for the first time. On March 13, Neuracle's implantable brain-computer interface system for hand motor function compensation received NMPA approval for market launch, entering clinical application as the world’s first invasive brain-computer interface medical device. The product employs epidural minimally invasive implantation and wireless power supply communication technology, suitable for patients with quadriplegia caused by C2-C6 cervical spinal cord injury. This milestone marks that China's brain-computer interface industry has achieved synchronization between top-level design and regulatory practice, transitioning from the initial concept development phase.
Shifting to later-stage clinical applications. We believe that as a multidisciplinary future industry, brain-computer interfaces have already gained an early-mover advantage in clinical progress in China. Approved devices will gradually enter hospital settings to accumulate real-world data, and the underlying software and hardware platforms, which have already validated safety, are expected to continuously iterate, optimize, and expand.
Indications. It is recommended to focus on specialized medical service providers who master core neurosurgical clinical resources and data entry points, as well as innovative medical device companies with invasive brain-computer interface technology platforms.
Risk Warning: Risks of escalating geopolitical conflicts; business implementation falling short of expectations; risks of intensified industry competition; uncertainties in mergers and acquisitions; uncertainties in drug development.